EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Evofem Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026
- Market cap
- $865.23K
- P/E (TTM)
- –
- Dividend yield
- –
Evofem Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|
| Phexxi [Member] | $18.20M | $16.80M | – | 99.9% | +8.3% |
| Planned Principal Operations on Product Development, Raising Capital, and Building Infrastructure | – | – | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Evofem Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.